JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Recent Progress in Triple Negative Breast Cancer Research
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Recent Progress in Triple Negative Breast Cancer Research
Mouh, Fatima Zahra; El Mzibri, Mohammed; Slaoui, Meriem; Amrani, Mariam;
  PDF(new window)
 Abstract
Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC.
 Keywords
Triple-negative breast cancer (TNBC);biomarkers;targeted therapy;
 Language
English
 Cited by
 References
1.
Aboulkassima T, Yasmeena A, Akil N, et al (2015). Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study. Human Vaccines Immunotherapeutics, 11, 951-5. crossref(new window)

2.
Ahn SG, Dong SM, Oshima A, et al (2013). LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat.

3.
Ahuja R, Jamal A, Nosrati N, et al (2014). Human oncogenic viruses and cancer. Cancer, Current Science, 107, 768-785.

4.
Alibek K, Kakpenova A, Baiken Y (2013). Role of infectious agents in the carcinogenesis of brain and head and neck cancers. Infectious Agents Cancer, 8, 32. crossref(new window)

5.
Alikanoglu AS, Yildirim M, Suren D, et al ( 2014). Expression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease. J Buon, 19, 430-4.

6.
Alluri P, Newman LA (2014). Basal-like and triple-negative breast cancers searching for positives among many negatives. surg oncol clin n am, 23, 567-77 crossref(new window)

7.
Andreeva AVand Kutuzov MA (2010). Cadherin 13 in cancer. Genes Chromosomes Cancer, 49, 775-90.

8.
Ansieau S, Bastid J, Doreau A, et al (2008). Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell, 14, 79-89. crossref(new window)

9.
Arai T, Miyoshi Y, Kim SJ, et al (2006). Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat, 100, 169-76. crossref(new window)

10.
Asirvatham AJ, Schmidt M, Gao B, et al (2006). Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinol, 147, 257-71. crossref(new window)

11.
Bae YK, Shim YR, Choi JH, et al (2005). Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat, 37, 233-40. crossref(new window)

12.
Bartel D P (2009). MicroRNA Target Recognition and Regulatory Functions. Cell, 136, 215-33. crossref(new window)

13.
Bauer KR, Brown M, Cress RD, et al (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the california cancer registry. Cancer, 109, 1721-8 crossref(new window)

14.
Ben Gacem R, Hachana M, Ziadi S, et al (2012). Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. Cancer Epidemiol, 36, 190-197. crossref(new window)

15.
Bentz BG, Haines III GK, Radosevich JA (2000). Glutathione S-transferase pi in squamous cell carcinoma of the head and neck. laryngoscope, 110, 1642-7. crossref(new window)

16.
Bofill-Mas S, Girones R (2001). Excretion and transmission of JCV in human populations. J Neurovirol ,7, 345-349 crossref(new window)

17.
Bosch FX, Broker TR, Forman D, et al (2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 31, 1-31. crossref(new window)

18.
Brooks JD, Weinstein M, Lin X, et al (1998). CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev, 7, 531-6.

19.
Brtko J (2007). Role of retinoids and their cognate nuclear receptors in breast cancer chemoprevention. Cent European J Public Health, 15, 3-6.

20.
Buckland G, Travier N, Cottet V, et al (2013). Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. Int J Cancer, 132, 2918-27. crossref(new window)

21.
Cairns P, Esteller M, Herman JG, et al (2001). Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res, 7, 2727-30.

22.
Carey LA (2011). Directed therapy of subtypes of triple-negative breast cancer. Oncologist, 16, 71-78.

23.
Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA, 295, 2492-502. crossref(new window)

24.
Castello A, M Pollan, Buijsse B, et al (2014). Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study. British J Cancer, 111, 1454-62. crossref(new window)

25.
Comen E, Davids M, Kirchhoff T, et al (2011). Relative contributions of BRCA1 and BRCA2 mutations to “triplenegative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat, 129, 185-190. crossref(new window)

26.
Corbex M, Bouzbid S, Traverse-Glehen A (2014). Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from Algeria compared with other types of breast cancer tumors. Plos one, 9, e114559. crossref(new window)

27.
Dawood S, (2010). Triple-negative breast cancer epidemiology and management options. Drugs, 70, 2247-58. crossref(new window)

28.
De Candia P, Akram M, Benezra R, et al (2006). Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Human Pathol, 37, 1032-41. crossref(new window)

29.
Del Valle L, Gordon J, Enam S, et al (2002) Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J Natl Cancer Inst, 94, 267-73 crossref(new window)

30.
Demokan S, Chuang A, Suoglu Y, et al (2012). Promoter methylation and loss of p16 (INK4a) gene expression in head and neck cancer. Head Neck, 34, 1470-5. crossref(new window)

31.
Dennison J B, Molina J R, Mitra S, et al (2013). Lactate dehydrogenase b: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res, 19, 3703-13. crossref(new window)

32.
Dent R, Trudeau M, Pritchard KI, et al (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34. crossref(new window)

33.
Dong T, Kang X, Liu Z, et al (2015). Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. Tumour Biol.

34.
Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al (2004). Promoter hypermethylation profile of kidney cancer. Clin Cancer Res, 10, 3972-9. crossref(new window)

35.
Ellmann L, Joshi MB, Resink TJ, et al (2012). BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells. Lab Invest, 92, 1788-800. crossref(new window)

36.
Feinberg AP (2004). The epigenetics of cancer etiology. Seminars Cancer Biol, 14, 427-432. crossref(new window)

37.
Feng W, Shen L, Wen S, et al (2007). Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res, 9, 57. crossref(new window)

38.
Fernandes A, Bianchi G , Feltri AP, et al (2015). Presence of human papillomavirus in breast cancer and its association with prognostic factors. Ecancer, 9, 548.

39.
Ford NA, Rossi EL, Barnett K, et al (2015). Omega-3-acid ethyl esters block the protumorigenic effects of obesity in mouse models of postmenopausal basal-like and claudin-low breast cancer. Cancer Prev Res, 8, 796-806. crossref(new window)

40.
Gao X, Wang H, Pollok KE, et al (2015). Activation of deathassociated protein kinase in human peritumoral tissue: A potential therapeutic target. J Clin Neurosci, 10, 1655-60.

41.
Gazinska P, Grigoriadis A, Brown JP, et al (2013). Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Modern Pathol, 1-12

42.
Gheibi A, Kazemi M, Baradaran A, et al (2012). Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: a potential biomarker for detection of breast cancer in patients. Adv Biomed Res, 1, 80

43.
Gonzalez-Angulo AM, Timms KM, Liu S, et al (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res, 17, 1082-9 crossref(new window)

44.
Goodwin PJ, Ennis M, Pritchard K I, et al (2009). Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. J Clin, 27, 3757-63. crossref(new window)

45.
Green JA, Robertson LJ, Clark AH (1993). Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer, 68, 235-9. crossref(new window)

46.
Gucalp A, Traina TA (2010).Triple-negative breast cancer: role of the androgen receptor, Cancer J, 16, 62-65. crossref(new window)

47.
Hachana M, Amara K, Ziadi S et al (2012). Investigation of human JC and BK polyomaviruses in breast carcinomas. Breast Cancer Res Treat, 133, 969-77. crossref(new window)

48.
Hafez MM, Al-Shabanah OA, Al-Rejaie SS, et al (2015). Increased hypermethylation of glutathione s-transferase p1, dna-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females. Asian Pac J Cancer Prev, 16, 541-9. crossref(new window)

49.
Haldipur P, Gillies GS, Janson OK, et al (2014). Foxc1 dependent mesenchymal signalling drives embryonic cerebellar growth. Elife, 16, 3.

50.
Han B, Audeh W, Jin Y, et al (2013). Biology and treatment of basal-like breast cancer.in cell and molecular biology of breast cancer, Eds Schatten H. Humana Press, Springer New York Heidelberg Dordrecht London Numbers, 2013947794

51.
Herschkowitz J I, He X, Fan C, et al (2008). The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res, 10, 5.

52.
Holleman A, den Boer ML, de Menezes RX, et al (2006). The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood, 107, 769-76. crossref(new window)

53.
Holt PR, Arber N, Halmos B, et al (2002). Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev, 11, 113-9

54.
Hudis CA and Gianni L (2011). Triple-negative breast cancer: an unmet medical need. Oncologist, 16 Suppl 1, 1-11.

55.
IARC (2012) Personal habits and indoor combustions. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans,. 100E, World Health Organization, ; http://monographs.iarc.fr/ENG/Monographs/vol100B/ mono100E.pdf Lyon, France.

56.
IARC (2012). Biological agents. Monographs on the Evaluation of Carcinogenic Risks to Humans,.100B, World Health Organization, ; http://monographs.iarc.fr/ENG/Monographs/vol100B/ mono100B.pdf Lyon, France.

57.
Imperiale MJ (2000). The human polyomaviruses, BKV and JCV: molecular pathogenesis of acute disease and potential role in cancer. Virol, 267, 1-7. crossref(new window)

58.
Inoue T, Ishida T, Sugio K, et al (1995). Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respirat, 62, 223-7. crossref(new window)

59.
Je EC, Lca BS, Ga GA (2013). The role of transcription factor twist in cancer cells. J Genet Syndr Gene, 4, 1-7.

60.
Jeronimo C, Usadel H, Henrique R, et al (2002). Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urol, 60, 1131-5. crossref(new window)

61.
Jha AK, Nikbakht M, Jain V, et al (2012). p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients. Oncol Lett, 3, 1331-5. crossref(new window)

62.
Jiao Q, Wu A, Shao G, et al (2014). The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thoracic Disease, 6, 1329-35

63.
Jones C, Ford E, Gillett C, et al (2004). Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res, 10, 5988-97 crossref(new window)

64.
Jung EJ, Kim IS, Lee EY, et al (2013). Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer. Ann Lab Med, 33, 431-40. crossref(new window)

65.
Kantor RR, Giardina SL, Bartolazzi A, et al (1991). Monoclonal antibodies to glutathione S-transferase piimmunohistochemical analysis of human tissues and cancers. Int J Cancer, 47, 193-201. crossref(new window)

66.
Khor GH, Froemming GR, Zain RB, et al (2013). DNA methylation profiling revealed promoter hypermethylationinduced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. Int J Med Sci, 10, 1727-39. crossref(new window)

67.
Kieff E and Rickinson AB (2001). Epstein-Barr virus and its replication Ed. 4 Fields B. N. Knipe D. M. Howley P. M. eds. Fields Virol, 2, 2511-75

68.
Kleeff J, Ishiwata T, Friess H, et al. The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res, 58, 3769 -72.

69.
Kneubil MC, Godoy AEF, Coelho GP, et al (2015). Prognostic factors correlation with androgen receptor (AR) in triple negative breast cancer (TNBC). J Clin Oncol, 2015 ASCO Annual Meeting, 33, 15.

70.
Koo JS, Jung W, Jeong J, et al (2009). The predictive role of e-cadherin and androgen receptor on in vitro chemosensitivity in triple negative breast cancer. Jpn J Clin Oncol, 39, 560-8. crossref(new window)

71.
Krishnan AV, Feldman D (2011). Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin d. annu. rev. pharmacol. Toxicol, 51, 311-36.

72.
Kunitake T, Kitamura T, Guo J, et al (1995) Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus. J Clin Microbiol, 33, 1448-51

73.
Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al (2011). Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer, 117, 3658-69. crossref(new window)

74.
Lee WH, Morton RA, Epstein JI, et al (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A, 91, 11733-7 crossref(new window)

75.
Lehmann BD and Pietenpol JA (2014). Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol, 232, 142-150. crossref(new window)

76.
Li N, Bi X, Zhang Y, et al (2011). Human papillomavirus infection and sporadic breast carcinoma risk: a metaanalysis. Breast Cancer Res Treat, 126, 515-20 crossref(new window)

77.
Li X, Li T, Chen D, et al (2016). Overexpression of lysinespecific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway. Oncol Rep, 35, 584-92. crossref(new window)

78.
Liu M, Mo QG, Wei CY, et al (2013). Platinum-based chemotherapy in triple-negative breast cancer: a metaanalysis. Oncol Lett, 5, 983-91. crossref(new window)

79.
Liu X, Nugoli M, Laferriere J, et al (2011). Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proc Natl Acad Sci U S A, 108, 774-9. crossref(new window)

80.
Liu Y, Burkhalter R, Symowicz J, et al (2012). Lysophosphatidic Acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells. J Oncol, 501492.

81.
Lux MP, Fasching PA, Beckmann MW (2006). Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med, 84, 16-28. crossref(new window)

82.
Maire V, Baldeyron C, Richardson M, et al (2013). TTK/hMPS1 is an attractive therapeutic target for triplenegative breast cancer. Plos one, 8, 5

83.
Maksimenko J, Irmejs A, Trofimovics G et al (2012). BRCA1 mutation in the triple- negative breast cancer group. Hereditary Cancer Clin Practice, 10, A15

84.
Martin LJ, Li Q, Melnichouk O, et al (2011) A randomized trial of dietary intervention for breast cancer prevention. Cancer Res, 71, 123-33. crossref(new window)

85.
Masferrer JL, Leahy KM, Koki AT, et al (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.

86.
Mazouni C, Fina F , Romain S, et al (2015). Outcome of Epstein- Barr virus-associated primary breast cancer. Molecular Clinical Oncol, 3, 295-8 crossref(new window)

87.
McCleland ML, Adler AS, Shang Y, et al (2012). An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res, 72, 5812-23 crossref(new window)

88.
McGhan LJ, McCullough AE, Protheroe CA, et al (2014). Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol, 21, 361-367 crossref(new window)

89.
McNamaraa KM, Yodaa T, Takagi K, et al (2013). Androgen receptor in triple negative breast cancer. J Steroid Biochemistry Molecular Biol, 133, 66-76. crossref(new window)

90.
Medimegh I, Omrane I, Privat M (2014). MicroRNAs expression in triple negative vs non triple negative breast cancer in tunisia: interaction with clinical outcome. Plos one, 9, 11

91.
Mehrotra J, Vali M, McVeigh M, et al (2004). Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res, 10, 3104-9. crossref(new window)

92.
Miedler J, Abdul-Karim F, Wang N, et al (2009). MUC1 expression in early-stage triple-negative breast cancer. J Cancer Res, 69, 1916-30. crossref(new window)

93.
Millikan RC, Newman B, Tse CK, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39. crossref(new window)

94.
Morales-Sanchez A and Fuentes-Panana EM (2014). Human viruses and cancer. Viruses, 6, 4047-79 crossref(new window)

95.
Morris GJ, Naidu S, Topham AK, et al (2007). Differences in breast carcinoma characteristics in newly diagnosed african- american and caucasian patients: a single-institution compilation compared with thenational cancer institute’s surveillance, epidemiology, and end results database. Cancer, 10, 876-84

96.
Mosalpuria k, Hall C, Krishnamurthy S, et al (2014). Cyclooxygenase 2 expression in non metastatic triple negative breast cancer patients. Molecular Clin Oncol, 2, 845-50. crossref(new window)

97.
Muendlein A, Rohde BH, Gasser K, et al (2015). Evaluation of BRCA1/2 mutational status among German and Austrian women with triple negative breast cancer. J Cancer Res Clin Oncol.

98.
Murai Y, Zheng HC, Abdel Aziz HO, et al (2007). High JC virus load in gastric cancer and adjacent non-cancerous mucosa. Cancer Sci, 98, 25-31. crossref(new window)

99.
Murillo G, Matusiak D, Benya RV, et al (2007). Chemopreventive Efficacy of 25-Hydroxyvitamin D3 in Colon Cancer. J Steroid Biochem Mol Biol, 103, 763-7. crossref(new window)